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Transient blepharoptosis is a feared complication after 
botulinum toxin-A (BTX-A) cosmetic injections into the 
upper third of the face. Alpha-adrenergic agonist eyedrops 
are usually employed to address this adverse effect.1-3 
However, response may vary among patients and their use 
may be associated with ocular adverse effects.2-4 The use of 
eyelid make-up might be an alternative approach to man-
age temporary upper eyelid ptosis. The authors had previ-
ous experience using a similar approach to conservatively 
manage severe myopathic blepharoptosis cases when sur-
gical correction was contraindicated.5
A retrospective case series was conducted and 
the authors have complied with the principles of the 
Declaration of Helsinki. Cases were collected from January 
2012 to December 2016.
After performing a skin testing at the retroauricular 
region 24 hours before, in order to rule out allergies 
to the product, six patients, who had received cos-
metic BTX-A injections elsewhere, were treated using 
a hypoallergenic eyelid make-up (Double eyelid glue, 
Elizabeth, Japan) as an alternative to manage transient 
blepharoptosis. This product is water soluble and can 
be easily removed. The product was applied daily by the 
patient at the eyelid crease with a swab and allowed to 
dry for one minute. Then, a plastic Y-shaped stick that 
comes with the product was placed within the eyelid 
crease and the upper lid was pushed upward. Thus, a 
deeper eyelid crease was induced, temporarily elevating 
the upper eyelid (Figure 1 and Video, which is availa-
ble online as Supplementary Material at www.aesthetic-
surgeryjournal.com). Patients were asked to remove the 
product every night.
All patients were female and the mean age was 
55.5 years (range, 37-69 years). In 4 of 6 cases, abobot-
ulinum toxin had been applied in the upper third of the 
face for cosmetic purposes (in 2 cases, the toxin used was 
unknown). Mean marginal reflex distance (MRD-1) was 
+1 (range, 0 to +2) before and +2.83 (range, +2 to +4) 
after the eyelid glue application. All patients had normal 
levator function and Bell phenomenon. Mean duration of 
the blepharoptosis was 5.67 weeks (range, 4-9 weeks). All 
patients reported satisfaction with improvement of the pal-
pebral fissure. Patient satisfaction was assessed in an office 
interview immediately after applying the eyelid make-up. 
No allergic reaction or other adverse effects were observed 
with the use of the product. Patients were followed up for 
3 months and after that period, all patients had sponta-
neous improvement of the blepharoptosis.
Upper lid ptosis after BTX-A applications may occur 
due to inadvertent diffusion of the drug into the levator 
palpebrae superioris muscle after glabellar, lateral perior-
bita, or lateral brow ptosis treatment. Eyelid ptosis may 
also be noted if a patient who presents preexisting and 
undiagnosed blepharoptosis compensated by the fronta-
lis muscle elevation receives injudicious treatment of the 
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forehead lines.1,2 Thus, careful evaluation before treatment 
is mandatory.
Recommendations to minimize migration of the drug 
into the levator muscle include: subcutaneous injections 
using concentrated small volumes; injecting at least 1 cm 
above the orbital rim when treating the glabella; use of 
onabotulinum toxin rather than abobotulinum toxin, due 
to the reported higher risk of blepharoptosis after the latter, 
probably due to its lower molecular weight. Furthermore, 
caution is needed when treating older patients whose 
orbital septum may be thinned.1,2 If even following all 
these recommendations, blepharoptosis occurs, use of the 
eyelid make-up is a temporary treatment option.
This type of eyelid make-up is very popular among East 
Asian women with a single eyelid who opt for a temporary 
approach to induce an eyelid crease. This type of product 
can be found in stores that feature Asian make-up and cos-
metic products, and online retailers, such as Amazon and 
Ebay. In the United States, prices vary between $5 and $15 
USD, according to the brand. Regarding the management 
of transient blepharoptosis, this technique can be used in 
Asians and non-Asians (Figure 2).
The authors had previously described the use of 
octyl-cyanoacrylate (liquid Band-Aid) as an alternative 
to manage severe cases of myopathic blepharoptosis.5 
Currently, liquid Band-Aid has been discontinued and the 
authors started using the eyelid make-up to temporarily 
treat blepharoptosis after BTX-A applications.
The eyelid make-up could elevate the upper eyelid on 
average 2 mm. Since most cases of blepharoptosis were 
mild to moderate, all patients reported a satisfactory 
improvement.
In the first attempt, the technique is not as easy as 
simply instilling eyedrops. However, after watching online 
tutorial videos made available by the companies that pro-
duce this type of make-up, and with some practice, the 
technique becomes easier. The greatest advantage is that 
the eyelid make-up is associated with much less adverse 
effects and ocular discomfort than the use of eye drops, 
such as apraclonidine. The use of alpha-adrenergic ago-
nist eyedrops may be associated with side effects such as: 
ocular hyperemia, pruritus, foreign body sensation, tear-
ing, discomfort, lid edema, dry mouth, transient loss of 
visual acuity, and allergic conjunctivitis.3,4 Furthermore, 
the use of alpha-adrenergic eye is not recommended in 
contact lens users.
The use of the eyelid make-up seems to be safe if used 
temporarily and removed every night. The risk associated 
to its use is similar to the use of other types of make-up 
(ie, local skin irritation). No adverse effects have been 
observed in the authors’ experience. To avoid local irrita-
tion, a skin test prior to its use is recommended. If irrita-
tion occurs, it will be limited to the skin, and the product 
can be easily removed with water.
In conclusion, the eyelid make-up is a simple, effec-
tive, inexpensive, and safe alternative to minimize bleph-
aroptosis that may occur after BTX-A cosmetic treatment. 
It could also be used to manage transient blepharoptosis 
after BTX-A application into the upper eyelid to treat facial 
dystonias. Further studies are needed in a larger cohort of 
patients.
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Figure 1. (A) The product is applied daily at the eyelid crease with a swab and allowed to dry for one minute. (B) The upper lid 
is pushed upward with the plastic Y-shaped stick and a deeper eyelid crease is induced, temporarily elevating the upper eyelid.
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This article contains supplementary material located online at 
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Figure 2. (A) This 58-year-old woman presented with right upper eyelid ptosis, noted one week after abobotulinum toxin-A 
injection. (B) Her right upper eyelid ptosis was temporarily treated with the eyelid make-up and an improvement of 2 mm in 
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